Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis to be addressed in this randomized phase III trial is that 4 months of
letrozole may be superior to surgery as primary therapy for early stage hormone receptor
positive breast cancer in postmenopausal women, provided that these patients will receive
definitive and radical surgery and adjuvant therapies as otherwise indicated at the
completion of preoperative letrozole.
Phase:
Phase 3
Details
Lead Sponsor:
Danish Breast Cancer Cooperative Group
Collaborators:
Danish Cancer Society Novartis The Danish Medical Research Council